Moleculin Biotech, Inc.
MBRX
$0.77
$0.011.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.47% | 3.37% | |||
| Depreciation & Amortization | 0.00% | -11.11% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.98% | 4.53% | |||
| Operating Income | 3.98% | -4.53% | |||
| Income Before Tax | 40.56% | -182.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.56% | -182.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.56% | -182.59% | |||
| EBIT | 3.98% | -4.53% | |||
| EBITDA | 3.98% | -4.55% | |||
| EPS Basic | 60.42% | -151.34% | |||
| Normalized Basic EPS | 56.85% | -144.84% | |||
| EPS Diluted | 60.42% | -151.34% | |||
| Normalized Diluted EPS | 56.85% | -144.84% | |||
| Average Basic Shares Outstanding | 37.73% | 84.21% | |||
| Average Diluted Shares Outstanding | 37.73% | 84.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||